Literature DB >> 15379667

Transcription factors in autoimmune diseases.

Martin Eggert1, Andreas Klüter, Uwe K Zettl, Gunther Neeck.   

Abstract

The analysis of the molecular basis of autoimmune diseases is currently under intense investigation. The identification of novel mechanisms underlying the pathogenesis of these diseases generates the possibility for the development of new therapeutic agents. In this review we summarize the results leading to novel insights concerning the molecular processes involved in the pathogenesis of rheumatoid arthritis, systemic lupus erythematodes, multiple sclerosis and diabetes type 1. We focus on the role of transcription factors such as nuclear factor kappa B, activator protein 1, peroxisome proliferator-activated receptor, vitamin D receptor and the glucocorticoid receptor that mediate pro- and anti-inflammatory effects and therefore represent direct or indirect targets for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15379667     DOI: 10.2174/1381612043383593

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  5 in total

1.  No effects of adalimumab therapy on the activation of NF-kappaB in lymphocytes from patients with severe rheumatoid arthritis.

Authors:  Marco Semmler; Ulrike Seeck; Beate Neustadt; Martin Schulz; Helmut Dotzlaw; Gunther Neeck; Martin Eggert
Journal:  Clin Rheumatol       Date:  2007-02-02       Impact factor: 2.980

Review 2.  Neuroendocrine-immune interactions in rheumatoid arthritis: mechanisms of glucocorticoid resistance.

Authors:  Marni N Silverman; Esther M Sternberg
Journal:  Neuroimmunomodulation       Date:  2008-07-29       Impact factor: 2.492

Review 3.  Vitamin D and human health: lessons from vitamin D receptor null mice.

Authors:  Roger Bouillon; Geert Carmeliet; Lieve Verlinden; Evelyne van Etten; Annemieke Verstuyf; Hilary F Luderer; Liesbet Lieben; Chantal Mathieu; Marie Demay
Journal:  Endocr Rev       Date:  2008-08-11       Impact factor: 19.871

4.  An evaluation of anti-TNF-alpha-therapy in patients with ankylosing spondylitis: imbalanced activation of NF kappa B subunits in lymphocytes and modulation of serum cortisol concentration.

Authors:  Martin Eggert; Ulrike Seeck; Marco Semmler; Ulrich Maass; Sabine Dietmann; Martin Schulz; Helmut Dotzlaw; Gunther Neeck
Journal:  Rheumatol Int       Date:  2007-01-23       Impact factor: 3.580

5.  T-5224, a selective inhibitor of c-Fos/activator protein-1, improves survival by inhibiting serum high mobility group box-1 in lethal lipopolysaccharide-induced acute kidney injury model.

Authors:  Mari Ishida; Masaaki Ueki; Jun Morishita; Masaki Ueno; Shunichi Shiozawa; Nobuhiro Maekawa
Journal:  J Intensive Care       Date:  2015-11-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.